skip to Main Content

CRUK Scientists Develop Drug that Targets KRAS Pathways

Newsfeed image, light gray text on dark gray background

A new study, funded by Cancer Research UK (CRUK) and Wellcome, has discovered a new way to target the KRAS mutation, which is found in a number of hard-to-treat cancer types.

A research team, led by Professors Caroline Springer and Richard Marais at the Cancer Research UK Manchester Institute, has developed a drug which blocks two pathways in the KRAS signalling pathway, known as RAF and SRC. Read more …

Back To Top